CD19/CD20 bispecific CAR-T cells

Developed for: B-cell non-Hodgkin lymphoma
Investigated by: Henan Cancer Hospital · Henan Hualong Biotechnology Company

today NCT03881761 · Ph 1

20192020202120222023202420252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT03881761	Feb 2019 → Jan 2021	B-cell non-Hodgkin lymphoma	Henan Cancer Hospital	Unknown	No outcome recorded

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	CD19/CD20 bispecific CAR-T cells	ClinicalTrials.gov intervention name — accepted as the source's own label NCT03881761 ↗
Target	CD19	“CD19/CD20 bispecific CAR-T cells” NCT03881761 ↗
Target	CD20	“CD19/CD20 bispecific CAR-T cells” NCT03881761 ↗